NasdaqCM - Delayed Quote USD

Lipocine Inc. (LPCN)

4.7977 +0.2777 (+6.14%)
At close: April 26 at 4:00 PM EDT
4.7983 +0.00 (+0.01%)
After hours: April 26 at 5:46 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Mahesh V. Patel Ph.D. Co-Founder, Interim Principal Financial Officer, Director, President & CEO 762.53k -- 1957
Ms. Krista Fogarty Principal Accounting Officer & Corporate Controller 321.07k -- 1968
Dr. Nachiappan Chidambaram Ph.D. Senior Vice President of Research & Development 385.71k -- 1969
Mr. Logan Morse Vice President of Sales, Marketing & Operations 413.58k -- 1970

Lipocine Inc.

675 Arapeen Drive
Suite 202
Salt Lake City, UT 84108
United States
801 994 7383 https://www.lipocine.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
17

Description

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Lipocine Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Lipocine Inc. Earnings Call

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
ASLN ASLAN Pharmaceuticals Limited
0.4153
-7.30%
 
CNTB Connect Biopharma Holdings Limited
1.3400
-0.74%
 
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
 
BNOX Bionomics Limited
1.0000
+3.49%
 
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
PTN Palatin Technologies, Inc.
1.8200
+5.81%